HNO International, Inc. 10-Q/A

Item 1. Financial Statements. HNO INTERNATIONAL, INC. CONDENSED BALANCE SHEETS (Unaudited) April 30, October 31, 2025 2024 ASSETS Current Assets Cash $ 72,614 $ 20,255 Accounts receivable 8,450 — Total Current Assets 81,064 20,255 Non-Current Assets Property and equipment, net 1,466,535 994,898 Long term asset, net — 112,026 Right-of-use asset 93,496 121,805 Total Non-Current Assets 1,560,031 1,228,729 TOTAL ASSETS $ 1,641,095 $ 1,248,984 LIABILITIES AND STOCKHOLDERS' DEFICIT LIABILITIES Current Liabilities Accounts payable $ 430,758 $ 138,029 Accrued payroll 8,881 17,762 Accrued interest payable 42,709 28,845 Lease liability 58,989 57,062 Payroll tax 2,838 2,838 Advances, related party 1,319,585 960,585 Convertible note payable, at fair value 59,985 — Customer deposits 99 99 Notes payable, related party 785,000 785,000 Total Current Liabilities 2,708,844 1,990,220 Non-Current Liability Lease liability 36,044 66,155 Long term notes payable, related party 590,000 590,000 Total Non-Current Liability 626,044 656,155 Total Liabilities 3,334,888 2,646,375 STOCKHOLDERS’ DEFICIT Preferred stock, par value $ 0.001 per share; 15,000,000 shares authorized — — Series A, par value $ 0.001 per share; 10,000,000 shares authorized; 5,000,000 and 5,000,000 shares issued and outstanding as of April 30, 2025 and October 31, 2024, respectively 5,000 5,000 Series B, par value $ 0.001 per share; 500,000 shares authorized; 360,000 and 0 shares issued and outstanding as of April 30, 2025 and October 31, 2024, respectively 360 — Common stock, par value $ 0.001 per share; 985,000,000 shares authorized; 80,150,491 and 419,437,865 shares issued and outstanding as of April 30, 2025 and October 31, 2024, respectively 80,150 419,438 Common stock payable 15,250 15,250 Common stock subscription receivable ( 13,750 ) ( 13,750 ) Additional paid-in capital 49,585,350 43,611,365 Accumulated deficit ( 51,366,153 ) ( 45,434,694 ) Total Stockholders’ Deficit ( 1,693,793 ) ( 1,397,391 ) TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT $ 1,641,095 $ 1,248,984 The accompanying notes are an integral part of these condensed unaudited financial statements. 5 HNO INTERNATIONAL, INC. CONDENSED STATEMENTS OF OPERATIONS (Unaudited) For the Three Months Ended April 30, For the Six Months Ended April 30, 2025 2024 2025 2024 (As Restated) (As Restated) Revenue $ 43,708 $ — $ 43,708 $ — Cost of goods sold — — — — Gross Profit 43,708 — 43,708 — Operating expenses Advertising and marketing 14,810 — 20,160 — General and administrative expenses 314,323 526,635 5,708,985 990,641 Depreciation and amortization 57,539 42,631 111,988 79,067 Total Operating Expenses 386,672 569,266 5,841,133 1,069,708 Other Income (Expenses) Interest income 5 5,192 5 5,492 Interest expense ( 6,932 ) ( 6,781 ) ( 13,864 ) ( 13,712 ) Loss on fair value of convertible note ( 14,985 ) — ( 14,985 ) — Loss on write-off of intangible asset ( 105,190 ) — ( 105,190 ) — Total Other (Expenses) ( 127,102 ) ( 1,589 ) ( 134,034 ) ( 8,220 ) Loss from Operations $ ( 470,066 ) $ ( 570,855 ) $ ( 5,931,459 ) $ ( 1,077,928 ) Net Loss $ ( 470,066 ) $ ( 570,855 ) $ ( 5,931,459 ) $ ( 1,077,928 ) PER SHARE AMOUNTS Basic and diluted net loss per share $ ( 0.01 ) $ ( 0.00 ) $ ( 0.03 ) $ ( 0.00 ) Weighted average number of common shares outstanding - basic and diluted 78,534,293 419,491,234 211,773,082 419,439,854 The accompanying notes are an integral part of these condensed unaudited financial statements. 6 HNO INTERNATIONAL, INC. CONDENSED STATEMENTS OF STOCKHOLDERS' DEFICIT For the three months and six months ended April 30, 2025 and 2024 (As Restated) (Unaudited) Series A Preferred Stock Series B Preferred Stock Common Stock Stock Share Subscription Additional Paid-in Accumulated Total Stockholders' Shares Amount Shares Amount Shares Amount Payable Receivable Capital Deficit Deficit Balance at October 31, 2023 (Restated) 5,000,000 $ 5,000 — $ — 419,341,584 $ 419,341 $ 32,251 $ ( 23,750 ) $ 41,470,177 $ ( 42,096,104 ) $ ( 193,085 ) Regulation A stock issuances — — — — 91,501 92 33,999 — 91,409 — 125,500 Net loss for the three months ended January 31, 2024 — — — — — — — — — ( 507,073 ) ( 507,073 ) Balance at January 31, 2024 (Restated) 5,000,000 $ 5,000 — $ — 419,433,085 $ 419,433 $ 66,250 $ ( 23,750 ) $ 41,561,586 $ ( 42,603,177 ) $ ( 574,658 ) Regulation A stock issuances — — — — 120,400 120 13,250 — 120,280 — 133,650 Net loss for the three months ended April 30, 2024 — — — — — — — — — ( 570,855 ) ( 570,855 ) Balance at April 30, 2024 (Restated) 5,000,000 $ 5,000 — $ — 419,553,485 $ 419,553 $ 79,500 $ ( 23,750 ) $ 41,681,866 $ ( 43,174,032 ) $ ( 1,011,863 ) Balance at October 31, 2024 5,000,000 $ 5,000 — $ — 419,437,865 $ 419,438 $ 15,250 $ ( 13,750 ) $ 43,611,365 $ ( 45,434,694 ) $ ( 1,397,391 ) Regulation D stock issuances — — — — 29,293 29 — — 14,971 — 15,000 Shares cancelled as per exchange agreement — — — — ( 360,000,000 ) ( 360,000 ) — — — — ( 360,000 ) Series B preferred stock issuances — — 360,000 $ 360 — — — — 359,640 — 360,000 Stock-based compensation — — — — 16,125,000 16,125 — — 5,076,432 — 5,092,557 Net loss for the three months ended January 31, 2025 — — — — — — — — — ( 5,461,393 ) ( 5,461,393 ) Balance at January 31, 2025 5,000,000 $ 5,000 360,000 $ 360 75,592,158 $ 75,592 $ 15,250 $ ( 13,750 ) $ 49,062,408 $ ( 50,896,087 ) $ ( 1,751,227 ) Regulation D stock issuances — — — — 4,558,333 4,558 — — 522,942 — 527,500 Net loss for the three months ended April 30, 2025 — — — — — — — — — ( 470,066 ) ( 470,066 ) Balance at April 30, 2025 5,000,000 $ 5,000 360,000 $ 360 80,150,491 $ 80,150 $ 15,250 $ ( 13,750 ) $ 49,585,350 $ ( 51,366,153 ) $ ( 1,693,793 ) The accompanying notes are an integral part of these condensed unaudited financial statements. 7 HNO INTERNATIONAL, INC. CONDENSED STATEMENTS OF CASH FLOWS (Unaudited) For the Six Months Ended April 30, 2025 2024 (As Restated) Cash Flow from Operating Activities Net loss $ ( 5,931,459 ) $ ( 1,077,928 ) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 111,988 79,067 Legal services provided in exchange for convertible note 45,000 — Loss on fair value of convertible note 14,985 — Loss on write-off of intangible asset 105,190 — Stock-based compensation 5,092,557 — Changes in operating assets and liabilities: Decrease in due from related party — 56,392 (Increase) in accounts receivable ( 8,450 ) — Increase in accrued interest receivable — ( 5,185 ) Increase/(Decrease) in accounts payable ( 106,116 ) ( 6,245 ) Increase/(Decrease) in accrued payroll ( 8,881 ) — Increase/(Decrease) in accrued interest payable 13,864 13,712 Increase in lease vendor payable — 498 Operating lease ROU assets and lease liabilities, net 125 568 (Decrease) increase in payroll taxes — ( 14,802 ) Net Cash Used in Operating Activities ( 671,197 ) ( 953,923 ) Cash Flows from Financing Activities Proceeds from related party advances 509,000 710,585 Repayment of related party advances ( 150,000 ) — Proceeds from security deposits — 100,000 Proceeds from sale of common stock subscription payable — 47,249 Proceeds from sale of common stock 542,500 211,901 Net Cash Provided by Financing Activities 901,500 1,069,735 Cash Flows from Investing Activities Purchase of property and equipment ( 177,944 ) ( 184,227 ) Purchase of long term asset — ( 89,285 ) Net Cash Used in Investing Activities ( 177,944 ) ( 273,512 ) Net increase (decrease) in cash 52,359 ( 157,700 ) Cash at beginning of period 20,255 235,159 Cash at end of period $ 72,614 $ 77,459 Supplemental Disclosure of Interest and Income Taxes Paid: Interest paid during the period $ — $ — Income taxes paid during the period $ — $ — Supplemental Disclosure for Non-Cash Investing and Financing Activities: Acquired property and equipment remaining in accounts payable $ 398,845 $ — Common stock cancellation per share exchange agreement $ ( 360,000 ) $ — Series B preferred stock issuance per exchange agreement $ 360,000 $ — Record right-to-use asset and lease liability per ASC 842 $ — $ 167,749 Convertible note issued in exchange for legal services, recorded at fair value $ 59,985 $ — The accompanying notes are an integral part of these condensed unaudited financial statements. 8 HNO INTERNATIONAL, INC. NOTES TO CONDENSED UNAUDITED FINANCIAL STATEMENTS APRIL 30, 2025 NOTE 1 – ORGANIZATION AND BASIS OF ACCOUNTING Organization HNO International, Inc. (the “Company”) was incorporated in the State of Nevada on May 2, 2005. The Company specializes in the design, integration, and development of green hydrogen-based clean energy technologies. The Company is committed to providing scalable products that help businesses and communities decarbonize, reduce emissions, and cut operational costs. HNO stands for Hydrogen and Oxygen. The Company is at the forefront of developing innovative solutions, such as the Compact Hydrogen Refueling System (CHRS) and the Compact Hydrogen Production System (CHPS), which can be used to produce hydrogen for various applications including fuel cell electric vehicles, hydrogen internal combustion engines, heating and cooking applications. The CHPS is highly scalable, capable of producing 100-2,000 (or more) kilograms of hydrogen per day for commercial use in various applications. In addition, the Company develops energy systems that complement the zero-emissions EV infrastructure, reduce harmful emissions, and cut maintenance costs of commercial diesel fleets. By integrating components from leading industry partners, the Company aims to transition fossil fuels to cleaner alternatives and promote lower emissions. NOTE 2 – FINANCIAL STATEMENT RESTATEMENT In connection with the Company’s re-audit of its financial statements for the year ended October 31, 2023, the Company’s management, in consultation with its independent registered public accounting firm, identified corrections to the valuation of service stock issued during the year ended October 31, 2023, and the termination of the patent agreement entered into on January 24, 2023. The corrections made that impact the condensed financial statements for the quarter ended April 30, 2024, are summarized as follows: Stock Price Valuation Adjustment: The valuation of the stock price was adjusted from $ 0.001 to $ 0.23 and there was an increase in stock-based compensation reflecting the revised valuation of stock. Equity Adjustments: There was a corresponding increase in additional paid-in capital and an adjustment in the accumulated deficit to reflect the revised stock valuation and related stock-based compensation. Termination of Patent Purchase Agreement: On March 13, 2025, the Company and Donald Owens mutually agreed to terminate the Patent Purchase Agreement as of January 24, 2023. As part of the termination, the patents were returned to Mr. Owens, and the 5,000,000 shares of Series A Preferred Stock were canceled. The $ 82,500 value previously reported in intangible assets and additional paid-in capital was reversed, resulting in a reduction in intangible assets. Additionally, the related amortization expense of $ 3,176 and the issuance of Series A Preferred Stock were removed from the financial statements. Reclassification of Expenses: Expenses incurred during the fiscal year ended October 31, 2023, and paid subsequently, have been reclassified to accounts payable as of October 31, 2023. This adjustment ensures that financial obligations are accurately reported in the period in which they were incurred. The restatement includes the initial recognition of right-of-use assets and corresponding lease liabilities on the balance sheet to properly reflect lease accounting in accordance with ASC 842. These adjustments have been reflected in the restated financial statements for the quarter ended April 30, 2024. Impact of the Restatement The impact of the restatement on the financial statements for the affected period is presented below. In addition to the below, the related notes to the financial statements have also been adjusted as appropriate to reflect the impact of the restatement. 9 The impact of the restatement on the line items within the previously reported Condensed Unaudited Statement of Operations for the three and six months ended April 30, 2024, previously filed is as follows: Schedule of statement of operations Statement of Operations for the three months ended April 30, 2024 As Previously Reported Adjustment As Restated Revenue $ — $ — $ — Cost of goods sold $ — $ — $ — Gross Profit $ — $ — $ — Operating expenses General and administrative expenses $ 526,635 $ — $ 526,635 Depreciation and amortization $ 36,809 $ 5,822 $ 42,631 Total Operating Expenses $ 563,444 $ 5,822 $ 569,266 Other Income (Expenses) Interest income $ 5,192 $ — $ 5,192 Interest expense $ ( 6,781 ) $ — $ ( 6,781 ) Total Other (Expenses) $ ( 1,589 ) $ — $ ( 1,589 ) Loss from Operations $ ( 565,033 ) $ ( 5,822 ) $ ( 570,855 ) Net Loss $ ( 565,033 ) $ ( 5,822 ) $ ( 570,855 ) PER SHARE AMOUNTS Basic and diluted net loss per share $ ( 0.00 ) $ — $ ( 0.00 ) Weighted average number of common shares outstanding - basic and diluted 419,491,234 — 419,491,234 Statement of Operations for the six months ended April 30, 2024 As Previously Reported Adjustment As Restated Revenue $ — $ — $ — Cost of goods sold $ — $ — $ — Gross Profit $ — $ — $ — Operating expenses General and administrative expenses $ 1,009,505 $ ( 18,864 ) $ 990,641 Depreciation and amortization $ 70,092 $ 8,975 $ 79,067 Total Operating Expenses $ 1,079,597 $ ( 9,889 ) $ 1,069,708 Other Income (Expenses) Interest income $ 5,492 $ — $ 5,492 Interest expense $ ( 13,712 ) $ — $ ( 13,712 ) Total Other (Expenses) $ ( 8,220 ) $ — $ ( 8,220 ) Loss from Operations $ ( 1,087,817 ) $ 9,889 $ ( 1,077,928 ) Net Loss $ ( 1,087,817 ) $ 9,889 $ ( 1,077,928 ) PER SHARE AMOUNTS Basic and diluted net loss per share $ ( 0.00 ) $ — $ ( 0.00 ) Weighted average number of common shares outstanding - basic and diluted 419,439,854 — 419,439,854 10 The impact of the restatement on the line items within the previously reported Condensed Unaudited Statement of Changes in Stockholders’ Deficit for the three and six months ended April 30, 2024, previously filed is as follows: Schedule of statement of changes in stockholders’ deficit Changes in Statement of Stockholders' Deficit for the three months ended April 30, 2024 As Previously Reported Adjustment As Restated Beginning Additional Paid-in Capital - Balance at January 31, 2024 $ 41,171,311 $ 390,275 $ 41,561,586 Beginning Accumulated Deficit - Balance at January 31, 2024 $ ( 42,132,662 ) $ ( 470,515 ) $ ( 42,603,177 ) Beginning Total Stockholders’ Deficit - Balance at January 31, 2024 $ ( 489,418 ) $ ( 85,240 ) $ ( 574,658 ) Series A preferred issued pursuant to patent agreement, shares 10,000,000 ( 5,000,000 ) 5,000,000 Series A preferred issued pursuant to patent agreement, amount $ 10,000 $ ( 5,000 ) $ 5,000 Net loss for the three months ended April 30, 2024 $ 565,033 $ 5,822 $ 570,855 Ending Additional paid in capital - Balance at April 30, 2024 $ 41,291,591 $ 390,275 $ 41,681,866 Ending Accumulated Deficit - Balance at April 30, 2024 $ ( 42,697,762 ) $ ( 476,270 ) $ ( 43,174,032 ) Ending Total Stockholders’ Deficit - Balance at April 30, 2024 $ ( 920,868 ) $ ( 90,995 ) $ ( 1,011,863 ) Changes in Statement of Stockholders' Deficit for the six months ended April 30, 2024 As Previously Reported Adjustment As Restated Beginning Additional Paid-in Capital - Balance at October 31, 2023 $ 41,079,902 $ 390,275 $ 41,470,177 Beginning Accumulated Deficit - Balance at October 31, 2023 $ ( 41,609,945 ) $ ( 486,159 ) $ ( 42,096,104 ) Beginning Total Stockholders’ Deficit - Balance at October 31, 2023 $ ( 92,201 ) ( 100,884 ) ( 193,085 ) Series A preferred issued pursuant to patent agreement, shares 10,000,000 ( 5,000,000 ) 5,000,000 Series A preferred issued pursuant to patent agreement, amount $ 10,000 $ ( 5,000 ) $ 5,000 Net loss for the six months ended April 30, 2024 $ 1,087,817 $ ( 9,889 ) $ 1,077,928 Ending Additional paid in capital - Balance at April 30, 2024 $ 41,291,591 $ 390,275 $ 41,681,866 Ending Accumulated Deficit - Balance at April 30, 2024 $ ( 42,697,762 ) $ ( 476,270 ) $ ( 43,174,032 ) Ending Total Stockholders’ Deficit - Balance at April 30, 2024 $ ( 920,868 ) $ ( 90,995 ) $ ( 1,011,863 ) 11 The impact of the restatement on the line items within the previously reported Condensed Unaudited Statement of Cash Flows for the six months ended April 30, 2024, previously filed is as follows: Schedule of statement of cash flows Statement of Cash Flows for the six months ended April 30, 2024 As Previously Reported Adjustment As Restated Cash Flow from Operating Activities Net loss $ ( 1,087,817 ) $ 9,889 $ ( 1,077,928 ) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization $ 70,092 $ 8,975 $ 79,067 Changes in operating assets and liabilities: Decrease in due from related party $ 56,392 $ — $ 56,392 Increase in accrued interest receivable $ ( 5,185 ) $ — $ ( 5,185 ) Increase/(Decrease) in accounts payable $ 15,813 $ ( 22,058 ) $ ( 6,245 ) Increase/(Decrease) in accrued interest payable $ 13,712 $ — $ 13,712 Increase in lease vendor payable $ — $ 498 $ 498 Operating lease ROU assets and lease liabilities, net $ 422 $ 146 $ 568 Increase (Decrease) in payroll taxes $ ( 14,802 ) $ — $ ( 14,802 ) Net Cash Used in Operating Activities $ ( 951,373 ) $ ( 2,550 ) $ ( 953,923 ) Cash Flows from Financing Activities Proceeds from related party advances $ 710,585 $ — $ 710,585 Proceeds from security deposits $ 100,000 $ — $ 100,000 Proceeds from sale of common stock subscription payable $ 47,249 $ — $ 47,249 Proceeds from sale of common stock $ 211,901 $ — $ 211,901 Net Cash Provided by Financing Activities $ 1,069,735 $ — $ 1,069,735 Cash Flows from Investing Activities Purchase of property and equipment $ ( 186,777 ) $ 2,550 $ ( 184,227 ) Purchase of long term asset $ ( 89,285 ) $ — $ ( 89,285 ) Net Cash Used in Investing Activities $ ( 276,062 ) $ 2,550 $ ( 273,512 ) Net increase (decrease) in cash $ ( 157,700 ) $ — $ ( 157,700 ) Cash at beginning of period $ 235,159 $ — $ 235,159 Cash at end of period $ 77,459 $ — $ 77,459 Supplemental Disclosure for Non-Cash Investing and Financing Activities: Record right-to-use asset and lease liability per ASC 842 $ ( 149,662 ) $ ( 18,087 ) $ ( 167,749 ) 12 NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying condensed financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”), and pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) and reflect all adjustments, consisting of normal recurring adjustments, which management believes are necessary to fairly present the financial position, results of operations and cash flows of the Company for the three and six months ended April 30, 2025. Out-of-Period Adjustment During the three months ended April 30, 2025, the Company recorded an out-of-period adjustment to write off the full gross amount of a previously capitalized intangible asset related to the prototype Compact Hydrogen Refueling Station (“CHRS”). The asset was originally recorded at $ 136,725 following the conversion of a SAFE investment into intellectual property. Upon further evaluation, management determined that the asset did not meet the criteria for capitalization. Management evaluated the error, both qualitatively and quantitatively, and concluded that the adjustment was not material to any prior interim or annual period. The Company recorded an expense of $ 105,190 , presented as “Loss on write-off of intangible asset” within other expenses for the quarter ended April 30, 2025. The remaining balance of the gross asset and related accumulated amortization were removed from the balance sheet as part of the adjustment. The previously recorded amortization from earlier periods was not reversed and remains reported in those respective periods. Use of Estimates The preparation of the financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. The management makes its best estimate of the outcome for these items based on information available when the financial statements are prepared. Cash and Cash Equivalents The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. As of April 30, 2025, and October 31, 2024, the Company did not hold any investments that qualify as cash equivalents. Therefore, the cash and cash equivalents line item in the balance sheet solely comprises cash. The Company maintains its cash balances at financial institutions, which at times may exceed federally insured limits. While the Company monitors the credit quality of its banking institutions, cash balances in excess of Federal Deposit Insurance Corporation (FDIC) insurance limits expose the Company to a certain degree of credit risk in the event of the financial institutions' failure. Stock-Based Compensation The Company accounts for stock-based compensation in accordance with Accounting Standards Codification (“ASC”) 718 Compensation - Stock Compensation (“ASC 718”). ASC 718 requires that the cost of equity instrument awards, issued in exchange for services, including those issued to employees and predominantly to consultants, be measured at the grant-date fair value. The Company does not adhere to a formal stock-based compensation plan; rather, it issues stock awards on a discretionary basis as part of compensation agreements with selected employees and consultants. Compensation for stock-based awards is recognized as a non-cash expense on the statement of operations. The fair value of restricted stock grants is determined using the closing market price on the grant date, adjusted for an appropriate discount to reflect the restrictions on transferability and marketability of the shares. The discount is calculated using a weighted average of comparable restricted stock transactions, which better reflects the economic impact of larger issuances and provides a more accurate representation of fair value under ASC 718. The cost is recognized over the period during which the award recipient is required to perform services, typically known as the vesting period. The total compensation cost related to vested stock-based awards is recognized after adjusting for estimated forfeitures at the time of vesting. The expense related to stock-based compensation is included within the same income statement lines as cash compensation for the consultants and employees who receive the awards, currently included in general and administrative expenses on the statement of operations as the Company does not allocate compensation costs to Costs of Goods Sold. As of the report date, the Company has not established any plans to issue dividends on stock-based awards. Any tax benefits arising from deductions for these awards are recorded in additional paid-in capital, provided they exceed the cumulative compensation cost recognized. 13 Income Taxes Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is provided for the amount of deferred tax assets that, based on available evidence, are not expected to be realized. The Company follows the provisions of ASC 740, Income Taxes , related to accounting for uncertainty in income taxes. ASC 740 prescribes a recognition threshold and measurement process for uncertain tax positions taken or expected to be taken in a tax return. The Company recognizes the financial statement effects of a tax position when it is more likely than not that, based on technical merits, the position will be sustained upon examination by the relevant taxing authorities. The Company had no unrecognized tax benefits as of April 30, 2025 and October 31, 2024, and does not anticipate any significant changes in unrecognized tax benefits within the next 12 months. Revenue Recognition We recognize revenue in accordance with ASC 606, Revenue from Contracts with Customers (“ASC 606”). The standard’s stated core principle is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To achieve this core principle, ASC 606 includes provisions within a five-step model that includes identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the performance obligations, and recognizing revenue when, or as, an entity satisfies a performance obligation. In certain arrangements where the Company facilitates the provision of goods or services provided by a third party, and does not take control of those goods or services, revenue is recognized on a net basis, limited to the margin or fee earned, consistent with the Company’s role as an agent under ASC 606-10-55-36 through 55-40. During the three months ended April 30, 2025, the Company recognized $ 43,708 in revenue related to the facilitation of delivery of hydrogen refueling equipment and related services. Based on its evaluation of the arrangement, the Company determined that it acted as an agent with respect to the facilitation of delivery of equipment, as it did not obtain control of the goods and the third-party vendor delivered directly to the customer. As a result, revenue was recognized on a net basis, excluding gross billings and associated third-party costs, in accordance with ASC 606. Basic and Diluted Net Loss per Common Share Basic loss per common share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding for each period. Diluted loss per share is computed by dividing the net loss by the weighted average number of shares of common stock outstanding plus the dilutive effect of shares issuable as common stock equivalents. As the Company is currently presenting net losses the weighted-average number of common shares outstanding excludes potential common stock equivalents because their inclusion would be anti-dilutive. Property and Equipment Property and equipment are carried at cost and, less accumulated depreciation. The cost of repairs and maintenance is expensed as incurred; major replacements and improvements are capitalized. When assets are retired or disposed of, the cost and accumulated depreciation are removed from the accounts, and any resulting gains or losses are included in the statement of operations in the year of disposal. The Company examines the possibility of decreases in the value of property and equipment when events or changes in circumstances reflect the fact that their recorded value may not be recoverable. The Company’s property and equipment consists of specialized hydrogen equipment, related processing systems, and vehicles. Depreciation is computed using the straight-line method over the estimated useful lives of the assets. Small equipment is depreciated over 3 years, vehicles are depreciated over 4 years, and large equipment is depreciated over 7 years. Schedule of estimated useful lives Useful life Small equipment 3 Years Large equipment 7 Years Vehicles 4 Years 14 Impairment of Long-Lived Assets The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable. To determine recoverability of a long-lived asset, management evaluates whether the estimated future undiscounted net cash flows from the asset are less than its carrying amount. If impairment is indicated, the long-lived asset would be written down to fair value. Fair value is determined by an evaluation of available price information at which assets could be bought or sold, including quoted market prices, if available, or the present value of the estimated future cash flows based on reasonable and supportable assumptions. Leases The Company accounts for leases in accordance with ASC 842, Leases (“ASC 842”). At contract inception, the Company determines if an arrangement is or contains a lease. Where the Company is the lessee, for each lease with a term greater than twelve months, the Company records a right-of-use asset and lease liability. A right-of-use asset represents the economic benefit conveyed to the Company by the right to use the underlying asset over the lease term. A lease liability represents the obligation to make lease payments arising from the use of the asset over the lease term. As most of the Company’s leases do not provide an implicit interest rate, the lease liability is calculated at lease commencement as the present value of unpaid lease payments using the Company’s estimated incremental borrowing rate. The incremental borrowing rate represents the rate of interest that the Company would have to pay to borrow an amount equal to the lease payments on a collateralized basis over a similar term and is determined using a portfolio approach based on information available at the commencement date of the lease. Leases with an initial expected term of 12 months or less are not recorded in the Balance Sheet and the related lease expense is recognized on a straight-line basis over the lease term. Fair value of financial instruments The Company’s financial instruments, including cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities are carried at cost, which approximates their fair value, due to the relatively short maturity of these instruments. The Company’s convertible promissory note issued on April 7, 2025, is classified as a liability and measured at fair value on a recurring basis in accordance with ASC 480, Distinguishing Liabilities from Equity , as the instrument requires settlement in a variable number of shares for a fixed monetary amount. The fair value of the convertible note was determined based on the conversion terms and observable market price of the Company’s common stock. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: · Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; · Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and · Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. 15 Assets and liabilities measured at fair value on a recurring basis as of April 30, 2025 were as follows: Schedule of fair value of assets and liabilities Total (Level 1) (Level 2) (Level 3) Assets $ — $ — $ — $ — Total assets $ — $ — $ — $ — Liabilities Convertible note payable 59,985 — — 59,985 Total liabilities $ 59,985 $ — $ — $ 59,985 NOTE 4 – GOING CONCERN On April 30, 2025, we had an accumulated deficit of $ 51,366,153 . We have not been able to generate sufficient cash from operating activities to fund our ongoing operations. We will be required to raise additional funds through public or private financing, additional collaborative relationships, or other arrangements until we are able to raise revenues to a point of positive cash flow. We are evaluating various options to further reduce our cash requirements to operate at a reduced rate, as well as options to raise additional funds, including obtaining loans and selling common stock. There is no guarantee that we will be able to generate enough revenue and/or raise capital to support operations. Based on the above factors, substantial doubt exists about our ability to continue as a going concern for one year from the issuance of these financial statements. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. NOTE 5 – PROPERTY AND EQUIPMENT Property and equipment consisted of the following: Schedule of property and equipment April 30, 2025 October 31, 2024 Vehicles $ 60,702 $ 60,702 Small equipment 32,943 32,943 Large equipment 1,669,953 1,093,166 Property and Equipment, Gross $ 1,763,598 $ 1,186,811 Less: Accumulated depreciation ( 297,064 ) ( 191,913 ) Property and Equipment, Net $ 1,466,534 $ 994,898 Depreciation expenses for the six months ended April 30, 2025 and 2024 were $ 105,151 and $ 68,041 , respectively. NOTE 6 – LEASES Operating leases The Company has an operating lease agreement for office space in Murrieta, California, expiring on November 30, 2026. On November 18, 2020, the Company entered into a lease commencing on December 1, 2020, and ending on November 30, 2023, for the office spaces located at 41558 Eastman Drive, Suites B and C, Murrieta, California 92562. The monthly rent was $4,183. Both suites are approximately 2,088 square feet of space. The Company’s principal executive office is located at 41558 Eastman Drive, Suite B, Murrieta, California 92562. Suite C is utilized for testing and research equipment . On November 14, 2023, the lease for Suite B was extended for 36 months to November 30, 2026. The monthly rental amount for Suite B was $2,501 for the period from December 1, 2023, to November 30, 2024, with an increase to $2,573 for the period from December 1, 2024, to November 30, 2025, and an increase to $2,647 for the period from December 1, 2025, to November 30, 2026 . On January 4, 2024, the lease for Suite C was extended for 34 months to November 30, 2026. The monthly rental amount for Suite C is $2,434 for the period from February 1, 2024, to November 30, 2024, with an increase to $2,506 for the period from December 1, 2024, to November 30, 2025, and an increase to $2,555 for the period from December 1, 2025, to November 30, 2026 . The Company determined the above office space leases and related extensions are classified as operating leases under ASC 842. Therefore, the Company recognized operating lease liabilities with corresponding Right-Of-Use ("ROU") assets based on the present value of the minimum rental payments of such leases . 16 As the Company’s leases do not provide an implicit interest rate, the lease liability is calculated at lease commencement as the present value of unpaid lease payments using the Company’s estimated incremental borrowing rate. The incremental borrowing rate represents the rate of interest that the Company would have to pay to borrow an amount equal to the lease payments on a collateralized basis over a similar term and is determined using a portfolio approach based on information available at the commencement date of the lease. As of April 30, 2025, the ROU asset was $ 93,496 and operating lease liabilities were $ 95,033 . The operating lease liabilities consist of a current portion of $ 58,989 and a non-current portion of $ 36,044 . The weighted average remaining lease term was 1.58 years and the weighted average discount rate was 4.14 %. Remaining lease term as of April 30, 2025: Schedule of remaining lease term Year Operating Lease Payment 2025 $ 30,455 2026 and above $ 65,986 Total Payments $ 96,441 NOTE 7 – COMMON STOCK The Company is authorized to issue 985,000,000 shares of common stock, par value $ 0.001 . Stock Issued During the quarter ended January 31, 2024, the Company issued 74,500 shares of common stock for $ 74,500 in cash under its Regulation A offering, qualified by the SEC on May 3, 2023. The Company also issued 17,001 Regulation A shares previously classified as common stock payable and sold 51,000 Regulation A shares, classified as $ 51,000 common stock payable. During the quarter ended April 30, 2024, the Company issued 69,400 shares of common stock for $ 69,400 in cash under its Regulation A offering, qualified by the SEC on May 3, 2023. The Company also issued 51,000 Regulation A shares previously classified as common stock payable and sold 64,250 Regulation A shares, classified as $ 64,250 common stock payable. During the quarter ended January 31, 2025, the Company entered into a Stock Subscription Agreement with accredited investors (under Rule 506 (b) of Regulation D under the Securities Act of 1933, as amended). Whereby the Company privately sold a total of 29,293 shares of its common stock for an aggregate cash purchase price of $ 15,000 . The proceeds from the sale of common stock will be used for operating capital. The shares were issued as ‘restricted securities’ under Rule 144 of the Securities Act. During the quarter ended January 31, 2025, the Company's Board of Directors granted approval for the issuance of 16,125,000 shares of our common stock valued at $ 5,092,557 , in exchange for services rendered to the Company. These shares were considered "restricted securities" under Rule 144 and were issued under the exemption provided by Section 4(a)(2) of the Securities Act. The issuance of these shares resulted in the recognition of stock-based compensation expense in the accompanying statement of operations. During the quarter ended April 30, 2025, the Company entered into Stock Subscription Agreements with accredited investors (under Rule 506(b) of Regulation D under the Securities Act of 1933, as amended). Whereby the Company privately sold a total of 4,558,333 shares of its common stock, for a cash purchase price of $ 527,500 . The proceeds from the sale of common stock will be used for operating capital. Stock Receivable As of April 30, 2025 and October 31, 2024, the Company issued 13,750 shares of common stock under Regulation A offering to various shareholders that have not yet paid for shares; therefore, $ 13,750 has been classified as common stock receivable. 17 Stock Payable As of April 30, 2025, the Company sold 15,250 shares of common stock under its Regulation A offering to various shareholders that have not yet been issued by the transfer agent; therefore, $ 15,250 has been classified as common stock payable. NOTE 8 – PREFERRED STOCK The Company is authorized to issue 15,000,000 shares of preferred stock, par value $ 0.001 . Series A Preferred Stock The Company is authorized to issue 10,000,000 shares of Series A preferred stock, par value $ 0.001 . On January 24, 2023, the Company issued 5,000,000 shares of its Series A Preferred Stock to Donald Owens, the Company’s Chief Executive Officer (CEO) and Chairman, valued at $ 82,500 for patents. On March 13, 2025, the Company and Mr. Owens mutually agreed to terminate the Patent Purchase Agreement as of January 24, 2023. As part of the termination, the 5,000,000 shares of Series A Preferred Stock were canceled (see Note 11). As of April 30, 2025, and October 31, 2024, the Company had 5,000,000 and 5,000,000 shares of Series A preferred stock issued and outstanding, respectively. Series B Preferred Stock The Company is authorized to issue 500,000 shares of Series B preferred stock, par value $ 0.001 . On January 2, 2025, the Company entered into a Share Exchange Agreement with the CEO. Pursuant to the agreement, the CEO exchanged 245,000,000 shares of the Company’s common stock for 245,000 shares of Series B Preferred Stock. On January 9, 2025, 245,000,000 shares of common stock held by Donald Owens were cancelled, and 245,000 shares of Series B Preferred Stock were issued to Donald Owens. On January 2, 2025, the Company entered into a Share Exchange Agreement with HNO Green Fuels, Inc. (“HNO Green Fuels), a related party. Pursuant to the agreement, HNO Green Fuels exchanged 115,000,000 shares of the Company’s common stock for 115,000 shares of Series B Preferred Stock. On January 9, 2025, 115,000,000 shares of common stock held by HNO Green Fuels, Inc. were cancelled, and 115,000 shares of Series B Preferred Stock were issued to HNO Green Fuels, Inc. As of April 30, 2025, and October 31, 2024, the Company had 360,000 and 0 shares of Series B preferred stock issued and outstanding, respectively. NOTE 9 – RELATED PARTY TRANSACTIONS Notes Payable, Related Party On December 1, 2021, the Company issued a note payable in the amount of $ 500,000 to HNO Green Fuels, Inc. (HNO Green Fuels) of which the CEO of the Company is also the Chief Executive Officer of HNO Green Fuels. This note bears an interest rate of 2 % per annum and had an original maturity date of January 1, 2023. During the year ended October 31, 2023, $ 65,000 of principal was repaid. On January 17, 2024, the Company entered into an extension to the promissory note, extending the maturity date to December 31, 2024, and waiving all prior defaults. On December 19, 2024, the Company executed another extension, further extending the maturity date to December 31, 2025 , and waiving all prior defaults. At April 30, 2025, there is $ 435,000 of principal and $ 4,314 of accrued interest due on this note. On May 31, 2022, the Company issued a note payable in the amount of $ 590,000 to HNO Green Fuels. This note bears an interest rate of 2 % per annum and has a maturity date of May 31, 2030. At April 30, 2025, there is $ 590,000 of principal and $ 34,430 of accrued interest due on this note. On September 29, 2022, the Company issued a note payable in the amount of $ 50,000 to HNO Green Fuels. This note bears an interest rate of 2 % per annum and had an original maturity date of October 31, 2023 . On January 17, 2024, the Company entered into an extension to the promissory note, extending the maturity date to December 31, 2024, and waiving all prior defaults. On December 19, 2024, the Company executed another extension, further extending the maturity date to December 31, 2025, and waiving all prior defaults. At April 30, 2025, there is $ 50,000 of principal and $ 496 of accrued interest due on this note. On October 20, 2022, the Company issued a note payable in the amount of $ 50,000 to HNO Green Fuels. This note bears an interest rate of 2 % per annum and had an original maturity date of November 20, 2023 . On January 17, 2024, the Company entered into an extension to the promissory note, extending the maturity date to December 31, 2024, and waiving all prior defaults. On December 19, 2024, the Company executed another extension, further extending the maturity date to December 31, 2025, and waiving all prior defaults. At April 30, 2025, there is $ 50,000 of principal and $ 496 of accrued interest due on this note. On March 1, 2023, the Company issued a note payable in the amount of $ 50,000 to HNO Green Fuels. This note bears an interest rate of 2 % per annum and had an original maturity date of March 1, 2024 . On March 1, 2024, the Company entered into an extension to the promissory note, extending the maturity date to December 31, 2024, and waiving all prior defaults. On December 19, 2024, the Company executed another extension, further extending the maturity date to December 31, 2025, and waiving all prior defaults. At April 30, 2025, there is $ 50,000 of principal and $ 496 of accrued interest due on this note. 18 On March 8, 2023, the Company issued a note payable in the amount of $ 50,000 to HNO Green Fuels. This note bears an interest rate of 2 % per annum and had an original maturity date of March 8, 2024 . On March 1, 2024, the Company entered into an extension to the promissory note, extending the maturity date to December 31, 2024, and waiving all prior defaults. On December 19, 2024, the Company executed another extension, further extending the maturity date to December 31, 2025, and waiving all prior defaults. At April 30, 2025, there is $ 50,000 of principal and $ 496 of accrued interest due on this note. On March 23, 2023, the Company issued a note payable in the amount of $ 50,000 to HNO Green Fuels. This note bears an interest rate of 2 % per annum and had an original maturity date of March 23, 2024 . On March 1, 2024, the Company entered into an extension to the promissory note, extending the maturity date to December 31, 2024, and waiving all prior defaults. On December 19, 2024, the Company executed another extension, further extending the maturity date to December 31, 2025, and waiving all prior defaults. At April 30, 2025, there is $ 50,000 of principal and $ 496 of accrued interest due on this note. On April 3, 2023, the Company issued a note payable in the amount of $ 50,000 to HNO Green Fuels. This note bears an interest rate of 2 % per annum and had an original maturity date of April 3, 2024 . On March 1, 2024, the Company entered into an extension to the promissory note, extending the maturity date to December 31, 2024, and waiving all prior defaults. On December 19, 2024, the Company executed another extension, further extending the maturity date to December 31, 2025, and waiving all prior defaults. At April 30, 2025, there is $ 50,000 of principal and $ 496 of accrued interest due on this note. On April 13, 2023, the Company issued a note payable in the amount of $ 20,000 to HNO Green Fuels. This note bears an interest rate of 2 % per annum and had an original maturity date of April 13, 2024 . On March 1, 2024, the Company entered into an extension to the promissory note, extending the maturity date to December 31, 2024, and waiving all prior defaults. On December 19, 2024, the Company executed another extension, further extending the maturity date to December 31, 2025, and waiving all prior defaults. At April 30, 2025, there is $ 20,000 of principal and $ 198 of accrued interest due on this note. On April 17, 2023, the Company issued a note payable in the amount of $ 30,000 to HNO Green Fuels. This note bears an interest rate of 2 % per annum and had an original maturity date of April 17, 2024 . On March 1, 2024, the Company entered into an extension to the promissory note, extending the maturity date to December 31, 2024, and waiving all prior defaults. On December 19, 2024, the Company executed another extension, further extending the maturity date to December 31, 2025, and waiving all prior defaults. At April 30, 2025, there is $ 30,000 of principal and $ 436 of accrued interest due on this note. As of April 30, 2025 and October 31, 2024, these current and long-term notes payable had an aggregate outstanding balance of $ 1,375,000 . As of April 30, 2025 and October 31, 2024, the Company has recorded $ 42,354 and $ 28,718 , respectively in accrued interest in connection with these notes in the accompanying condensed unaudited financial statements. Advances from Related Party During the year ended October 31, 2024, the Company’s CEO, advanced $ 950,585 to the Company to cover operating expenses. During the year ended October 31, 2024, HNO Green Fuels advanced $ 10,000 to the Company to cover operating expenses. During the three months ended January 31, 2025, the Company’s CEO, advanced $ 16,000 to the Company to cover operating expenses. During the three months ended January 31, 2025, HNO Green Fuels, advanced $ 343,000 to the Company to cover operating expenses. During the three months ended April 30, 2025, the Company repaid $ 20,000 to Donald Owens as partial repayment of previously advanced funds. During the three months ended April 30, 2025, HNO Green Fuels advanced an additional $ 150,000 and the Company repaid $ 130,000 as partial repayment of previously advanced funds. As of April 30, 2025 and October 31, 2024, related party advances had an outstanding balance of $ 1,319,585 and $ 960,585 , respectively. 19 NOTE 10 – CONVERTIBLE PROMISSORY NOTE On April 7, 2025, the Company entered into a Legal Services Agreement with Newlan Law Firm, PLLC, pursuant to which the Company issued a $ 45,000 principal amount convertible promissory note in payment of legal services. This convertible promissory note is convertible any time beginning 180 days from its issue date, bears interest at 8 % per annum and is due in April 2026. The conversion price under this convertible promissory note is equal to 75% of the closing price of the Company’s common stock on the trading day immediately preceding the date of conversion. On the issuance date, April 7, 2025, the Company determined the fair value of the note to be $ 59,985 and recorded the full amount as a liability. The excess of $ 14,985 over the $ 45,000 principal amount was recognized as a loss on fair value of convertible note in the condensed statements of operations. As of April 30, 2025, the Company would have accrued $ 227 in interest based on the 8 % per annum rate applied to the $ 45,000 principal balance. This amount was not required to be recorded separately due to the fair value measurement of the convertible promissory note. Following is the maturity schedule for the Company’s convertible notes payable as of April 30, 2025: Schedule of maturity convertible notes payable Fiscal year ended October 31, Amount Due 2025 $ — 2026 $ 45,000 NOTE 11 – TERMINATION OF PATENT AGREEMENT Patent Purchase Agreement On January 24, 2023, the Company entered into a Patent Purchase Agreement with the Company’s CEO, to acquire several patents related to hydrogen supplemental systems for on-demand hydrogen generation for internal combustion engines and a method and apparatus for increasing combustion efficiency and reducing particulate matter emissions in jet engines. In exchange for these patents, the Company issued 5,000,000 shares of its Series A Preferred Stock to Mr. Owens, valued at $ 82,500 . Termination of Patent Purchase Agreement On March 13, 2025, the Company and Donald Owens mutually agreed to terminate the Patent Purchase Agreement as of January 24, 2023. As part of the termination, the patents were returned to Mr. Owens, and the 5,000,000 shares of Series A Preferred Stock were canceled. See Note 2 – Correction of Previously Issued Financial Statements. A copy of the Termination Agreement was attached to the Company’s Annual Report on Form 10-K as Exhibit 10.27. NOTE 12 – SUBSEQUENT EVENTS Subsequent events have been evaluated through June 20, 2025, which represents the date the financial statements were available to be issued, and no events, other than discussed below have occurred through that date that would impact the financial statements. Common Stock Issued The Company entered into a Stock Subscription Agreement with an accredited investors (under Rule 506(b) of Regulation D under the Securities Act of 1933, as amended), whereby the Company privately sold a total of 3,700,000 shares of its common stock, $ 0.001 par value per share (“common stock”), for a cash purchase price of $ 185,000 . The Company issued 500,000 shares on May 13, 2025, 1,000,000 shares on May 23, 2025, 400,000 shares on May 30, 2025, 300,000 shares on June 2, 2025, 1,000,000 on June 5, 2025 and 500,000 on June 18, 2025 as "restricted securities" under Rule 144 of the Securities Act. The Company intends to use the proceeds for general working capital purposes. 20